Loading...
XASX
MYX
Market cap155mUSD
Oct 09, Last price  
2.66AUD
1D
-3.27%
1Q
-7.32%
Jan 2017
-90.11%
IPO
-65.00%
Name

Mayne Pharma Group Ltd

Chart & performance

D1W1MN
XASX:MYX chart
P/E
8.83
P/S
0.56
EPS
0.30
Div yield, %
—
Shrs. gr., 5y
5.52%
Rev. gr., 5y
-0.87%
Revenues
384m
-5.98%
140,112820,8141,039,88137,043,98848,768,00051,078,00082,262,000142,181,000140,324,000267,280,000572,595,000530,313,000525,208,000456,985,000400,781,000157,147,000183,586,000388,151,000408,095,000383,676,000
Net income
24m
P
-1,823,975-3,472,806-3,761,3183,253,1191,679,0006,153,000-2,843,00021,290,0007,759,00037,355,00088,567,000-133,984,000-279,203,000-92,789,000-208,423,000-281,286,000117,249,000-174,233,000-93,836,00024,473,000
CFO
16m
-10.59%
-1,238,716-3,025,908-3,589,83210,255,6004,086,00013,387,0006,845,00026,136,00022,420,00053,504,000-15,237,000121,498,000106,606,00099,777,00047,256,000-7,206,000-43,123,000-15,300,00017,469,00015,619,000
Dividend
Jan 18, 20230.0272 AUD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Mayne Pharma Group Limited is an Australian-headquartered specialty pharmaceutical enterprise, engaged in the development, production, and marketing of both patented (branded) and generic drug formulations. Its commercial reach spans Australia, New Zealand, North America (covering the United States and Canada), Europe, and Asia. The company's operations are divided into four main segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. Beyond its own product lines, Mayne Pharma offers sophisticated oral drug delivery technologies and comprehensive contract services—including pharmaceutical development, manufacturing, and analytical testing—to other businesses. Its strategic focus areas for specialty product distribution include dermatology, women's health, and infectious disease treatments. Originally established in 2005, the company operated under the name Halcygen Pharmaceuticals Limited before rebranding to Mayne Pharma Group Limited in November 2010. Its principal office is located in Salisbury South, Australia.

Key people

President - International Operations · since 2017
John Ross
President - Mayne Pharma USA · since 2017
Kate Rintoul
Executive Vice President, General Counsel · since 2015
Brant Schofield
Executive Vice President - Specialty Brands Division · since 2018
Ilana Stancovski
Chief Scientific Officer · since 2017
Andrew Herdman
Vice President, Group Human Resources
Scott Anthony Richards
Chief Executive Officer, Managing Director, Executive Director · since 2012
Peter Paltoglou
Chief Development Officer, Head of M&A · since 2016
Nick Freeman
Group Chief Financial Officer, Company Secretary · since 2017
Laura Loftus
Company Secretary · since 2020
Patrick J. Blake
Independent Non-Executive Director · since 2018
Independent Non-Executive Director · since 2018
Nancy Dolan
Independent Non-Executive Director · since 2016
Ian Frank Scholes
Independent Non-Executive Director · since 2007
IPO date
Jun 29, 2007
Employees
850
Domiciled in
AU
Incorporated in
AU
Headquarters & legal address
1538 Main North Road,Salisbury South
Adelaide, SA 5106
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT